NeuroBo Pharmaceuticals, Inc. (NRBO)

NASDAQ: NRBO · IEX Real-Time Price · USD

3.370

-0.030 (-0.88%)

At close: Apr 19, 2024, 4:00 PM

3.440

+0.070 (2.08%)

After-hours: Apr 19, 2024, 4:56 PM EDT

NeuroBo Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Selling, General & Admin	6.73	8.64	8.75	7.85	2.7	1.61	10.44	5.96	3.18	0.21
Research & Development	9.16	2.78	6.55	4.53	5.32	5.07	22.69	8.74	3.99	0.05
Other Operating Expenses	0	8.21	0	17.34	12.15	8.82	0.01	0	0.91	0
Operating Expenses	15.89	19.63	15.3	29.72	20.18	15.49	33.13	14.7	8.08	0.27
Operating Income	-15.89	-19.63	-15.3	-29.72	-20.18	-15.49	-33.13	-14.7	-8.08	-0.27
Interest Expense / Income	0	2.19	0	0	0.02	0.04	0.29	-0.11	0.76	0.06
Other Expense / Income	-3.42	-7.85	-0.01	-0.04	1.11	0	-	-	0.19	-0
Pretax Income	-12.47	-13.97	-15.28	-29.68	-21.31	-15.53	-33.42	-14.59	-9.03	-0.32
Net Income	-12.47	-13.97	-15.28	-29.68	-21.31	-15.53	-33.42	-14.59	-9.03	-0.32
Preferred Dividends	0	0	0	0	0	0	0	0.37	4.02	0
Net Income Common	-12.47	-13.97	-15.28	-29.68	-21.31	-15.53	-33.42	-14.95	-13.04	-0.32
Shares Outstanding (Basic)	5	0	0	0	0	0	0	0	0	0
Shares Outstanding (Diluted)	5	0	0	0	0	0	0	0	0	0
Shares Change	1476.33%	233.62%	42.72%	210.43%	22.88%	926.78%	78.20%	102.09%	88.58%	-
EPS (Basic)	-2.46	-43.42	-158.48	-439.24	-979.30	-876.09	-19381.94	-15421.54	-27242.72	-1260.13
EPS (Diluted)	-2.46	-43.42	-158.48	-439.24	-979.30	-876.09	-19381.94	-15421.54	-27242.72	-1260.13
Free Cash Flow	-10.85	-11.7	-15.14	-10.77	-7.25	-14.45	-26.9	-11.04	-5.43	-0.2
Free Cash Flow Per Share	-2.14	-36.38	-156.98	-159.37	-333.24	-816.05	-15597.64	-11406.45	-11339.35	-768.95
EBITDA	-12.46	-11.75	-15.21	-29.61	-21.27	-15.49	-33.13	-14.7	-8.27	-0.27
Depreciation & Amortization	0.01	0.03	0.07	0.07	0.02	0	0	0	0	0
EBIT	-12.47	-11.78	-15.28	-29.68	-21.29	-15.49	-33.13	-14.7	-8.27	-0.27

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).